Ann: Final Evidence Package Submitted to Health Canada - Updated, page-9

Quite the opposite. I would be very surprised if there wasn't a Cap Raise.

They have $15m left in cash.
Their cashburn for the last 2 quarters has been around $7.5m each quarter.

The cost to run such a facility and hire a team of workers and get it running are only just beginning.

There is almost no way they can buy the equipment, hire the staff, complete all licensing, complete euGMP certification and run the facility without raising more capital.

Medipharm Labs built a new facility in Wonthaggi and running's costs are over $3m per month and that's servicing around 10 different manufacturers.

Althea May go bankrupt trying to run this facility. Also with the fact that they are trying to run this from overseas, the risks are amplified.

Peak was a high risk move: High Stakes, High Risks